MeiraGTx Holdings plc — Q2 2023 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2023. Unaudited consolidated results. MeiraGTx is a clinical-stage gene therapy company with six programs in clinical development; it has no approved products and has not generated product-sale revenue.
Financial results
| Metric (USD millions, except per-share data) | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| License revenue, related party | 3.5 | 10.8 | 6.9 | 16.4 |
| Operating expenses | 32.3 | 34.5 | 67.4 | 68.9 |
| Loss from operations | (28.8) | (23.8) | (60.5) | (52.5) |
| Net loss | (29.6) | (34.0) | (59.9) | (65.0) |
| Basic and diluted loss per share | (0.53) | (0.76) | (1.15) | (1.46) |
| Operating cash used | — | — | (66.4) | (36.1) |
License revenue reflects amortization of Janssen upfront and milestone payments, not product sales. Janssen research and development reimbursements are recorded as offsets to R&D expense: $21.8 million in Q2 2023 and $44.4 million in the first half, versus $16.2 million and $29.5 million, respectively, in 2022.
Q2 net loss improved year over year, mainly because a $10.4 million foreign-currency loss in Q2 2022 became a $1.9 million gain in Q2 2023. However, operating loss widened as lower license revenue more than offset lower operating expenses. For the first half, net loss narrowed despite a larger operating loss, primarily reflecting the year-over-year foreign-currency swing. The filing does not present a conventional operating margin; the company remained loss-making.
Liquidity, cash flow and debt
- Cash and cash equivalents were $92.8 million at June 30, 2023, down from $115.5 million at December 31, 2022. Related-party receivables, primarily due from Janssen, were $32.7 million.
- First-half cash used in operations was $66.4 million; capital expenditures were $13.6 million. A $62.0 million gross private placement, or $57.9 million net proceeds after issuance costs, contributed to financing cash flow.
- Current assets were $143.1 million and current liabilities $71.8 million. Accumulated deficit was $530.1 million.
- Debt consisted of $75.0 million principal under the Perceptive note financing; the balance sheet reported the note at $71.6 million net of discount. The annual floating interest rate was 14.81% at June 30, 2023; the notes mature August 2, 2026 and are interest-only during the term. First-half interest expense was $6.4 million.
- Management estimated available cash, Janssen receivables and expected collaboration funding would support operating expenses and capital spending into Q2 2025, subject to assumptions. The financial-statement liquidity note separately states that cash and related-party receivables were expected to cover expenses for at least 12 months from issuance.
Material changes and operating developments
- May 2023 private placement issued 10.8 million ordinary shares at $5.75 per share for $62.0 million gross proceeds. Shares outstanding rose to 59.5 million at June 30, from 48.5 million at year-end 2022.
- First-half gross R&D costs increased to $86.7 million from $76.6 million, driven particularly by bota-vec and AAV-hAQP1 clinical work. Janssen reimbursement increased to $44.4 million, reducing reported net R&D expense to $42.3 million, down from $47.1 million.
- G&A increased to $25.2 million from $21.8 million for the first half, primarily due to legal and accounting fees and payroll-related costs.
- Cash used in operations rose to $66.4 million from $36.1 million year over year, while investing cash use fell to $13.6 million from $26.5 million.
Outlook, risks and contingencies
- Management said enrollment targets had been surpassed in the pivotal Phase 3 LUMEOS trial of bota-vec for X-linked retinitis pigmentosa and expected a BLA submission in 2024. This is a target, not an assurance of submission or approval.
- The company initiated a Phase 2 randomized, placebo-controlled AAV-hAQP1 study for radiation-induced xerostomia; management reported encouraging Phase 1 symptom and saliva-flow observations and anticipated presenting full data at a future medical meeting.
- AAV-GAD Parkinson’s disease Phase 1 bridging-trial enrollment was anticipated to be completed in Q3 2023. The company also reported that its Shannon, Ireland quality-control facility had received commercial MIA authorization for QC testing.
- Management expects R&D and G&A costs to rise as clinical programs, manufacturing capacity and public-company operations advance. The company expects continued losses and will require additional capital; future financing may dilute shareholders or be unavailable on acceptable terms.
- Perceptive debt is secured by manufacturing facilities, certain cash and subsidiary interests and includes restrictive covenants. The company reported compliance at June 30, 2023, including having enrolled in the Phase 3 AAV-RPGR trial by the required date. A covenant also requires the Shannon facility to meet applicable GMP requirements by December 31, 2023.
- On August 10, 2023, after quarter-end, the note agreement was amended to let the company request an additional $25 million tranche through August 2, 2024, subject to agreement terms; previously Perceptive had discretion over the request. The amendment also increased the early-redemption fee.
- Key risks include clinical and regulatory uncertainty, manufacturing and GMP execution, reliance on Janssen collaboration funding, capital needs, variable-rate debt, and foreign-exchange exposure. The company estimated that a 10% unfavorable currency move would have increased first-half foreign-currency loss by approximately $28.6 million. No material legal proceedings or new material commitments or contingencies were reported.
Important facts for investors to verify
- Whether LUMEOS enrollment, trial results and the targeted 2024 BLA submission remain on schedule, and what the final clinical and regulatory data show.
- Actual cash burn, collection timing of the $32.7 million Janssen receivable, collaboration funding and the assumptions behind the projected runway into Q2 2025.
- Shannon facility GMP readiness by the covenant deadline and any effects on clinical or manufacturing timelines.
- Debt cost and covenant compliance: the 14.81% floating rate, collateral, early-redemption terms and availability and conditions of the potential $25 million tranche.
- Share dilution from the private placement and outstanding equity awards, and the sensitivity of reported results and cash needs to currency movements.